Merck KGaA (MRK) Rating Reiterated by J P Morgan Chase & Co

J P Morgan Chase & Co restated their neutral rating on shares of Merck KGaA (FRA:MRK) in a research report report published on Wednesday.

Other research analysts have also recently issued research reports about the stock. BNP Paribas set a €114.00 ($135.71) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Saturday, May 20th. DZ Bank AG reaffirmed a neutral rating on shares of Merck KGaA in a report on Saturday, May 20th. Berenberg Bank set a €106.00 ($126.19) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Saturday, May 20th. S&P Global set a €115.00 ($136.90) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, May 19th. Finally, Nord/LB set a €114.00 ($135.71) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, May 19th. Fourteen research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of €107.71 ($128.23).

Shares of Merck KGaA (MRK) opened at 95.623 on Wednesday. The company has a market capitalization of €41.57 billion and a PE ratio of 24.928. Merck KGaA has a 52-week low of €89.00 and a 52-week high of €115.00. The firm’s 50-day moving average price is €93.50 and its 200 day moving average price is €102.64.

TRADEMARK VIOLATION WARNING: This article was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/09/10/merck-kgaa-mrk-rating-reiterated-by-j-p-morgan-chase-co.html.

About Merck KGaA

.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply